Sunday, October 28, 2007
CLINICAL DATA ACQUIRES EPIDAUROS BIOTECHNOLOGIE AG.
Abstract:Clinical Data, Inc. (NASDAQ:CLDA), Newton, Mass., has acquired privately held Epidauros Biotechnologie AG of Bernried, Germany, in a cash transaction valued at 8.75 million euros (or approximately $11.84 million). Epidauros brings to Clinical Data an established portfolio of proprietary genetic biomarkers, expertise in genetic biomarker discovery, relationships with leading diagnostic companies, and a fast- growing pharmacogenomics services business.
Among the strategic assets acquired by Clinical Data in the transaction is a significant intellectual property portfolio that includes biomarkers in genes relating to prominent drug transporters such as MDR1, OCT1, MRP1, and important cytochrome P450 drug metabolizing genes, such as CYP2B6 and CYP2D6. MDR1 encodes P-glycoprotein, a key protein involved in drug transport that is known to modulate drug disposition. In addition, the genes CYP2B6, OCT1, and MRP1 are implicated in the absorption, distribution, and metabolism of many drugs that span a variety of therapeutic classes and indications, and are likely to be important in both response and safety profiles for these drugs.Clinical Data's president and CEO, Drew Fromkin, said, "We are pleased to ...
COPYRIGHT 2007 Worldwide VideotexArticle Information:Published in: Worldwide BiotechIssue Number:
10Volume Number: 19Date Published: 01 October 2007Language: EnglishWord Count:
930The subject scope of this article includes:Medical equipment industryCytochrome P-450Companies mentioned in this article include:Clinical Data Inc.Tickers related to this article include:CLDAProduct Codes and Terms related to this article:
3840000 : Medical Instruments & SuppliesNAIC Codes and Terms related to this article:
3391 : Medical Equipment and Supplies ManufacturingSIC Codes and Terms related to this article:3840 : Medical Instruments and Supplies
Among the strategic assets acquired by Clinical Data in the transaction is a significant intellectual property portfolio that includes biomarkers in genes relating to prominent drug transporters such as MDR1, OCT1, MRP1, and important cytochrome P450 drug metabolizing genes, such as CYP2B6 and CYP2D6. MDR1 encodes P-glycoprotein, a key protein involved in drug transport that is known to modulate drug disposition. In addition, the genes CYP2B6, OCT1, and MRP1 are implicated in the absorption, distribution, and metabolism of many drugs that span a variety of therapeutic classes and indications, and are likely to be important in both response and safety profiles for these drugs.Clinical Data's president and CEO, Drew Fromkin, said, "We are pleased to ...
COPYRIGHT 2007 Worldwide VideotexArticle Information:Published in: Worldwide BiotechIssue Number:
10Volume Number: 19Date Published: 01 October 2007Language: EnglishWord Count:
930The subject scope of this article includes:Medical equipment industryCytochrome P-450Companies mentioned in this article include:Clinical Data Inc.Tickers related to this article include:CLDAProduct Codes and Terms related to this article:
3840000 : Medical Instruments & SuppliesNAIC Codes and Terms related to this article:
3391 : Medical Equipment and Supplies ManufacturingSIC Codes and Terms related to this article:3840 : Medical Instruments and Supplies
Subscribe to:
Posts (Atom)